

“Horizon partnerships in the health sector: the past and the future”

# Fostering an ERA for Health Candidate European Partnership

18 November 2021

Ignacio Baanante

[ibaanante@isciii.es](mailto:ibaanante@isciii.es)

Institute of Health Carlos III, Spain



# Overview of 49 candidate European Partnerships

## HORIZON EUROPE PILLAR II - Global challenges & European industrial competitiveness

CLUSTER 1: Health	CLUSTER 4: Digital, Industry & Space	CLUSTER 5: Climate, Energy & Mobility	CLUSTER 6: Food, Bioeconomy, Agriculture, ...
Innovative Health Initiative	Key Digital Technologies	Clean Hydrogen	Circular Bio-based Europe
Global Health Partnership	Smart Networks & Services	Clean Aviation	Rescuing Biodiversity to Safeguard Life on Earth
Transformation of health systems	High Performance Computing	Single European Sky ATM Research 3	Climate Neutral, Sustainable & Productive Blue Economy
Chemicals risk assessment	European Metrology (Art. 185)	Europe's Rail	Water4All
ERA for Health	AI-Data-Robotics	Connected and Automated Mobility (CCAM)	Animal Health & Welfare*
Rare diseases*	Photonics	Batteries	Accelerating Farming Systems Transitions*
One-Health Anti Microbial Resistance*	Made in Europe	Zero-emission waterborne transport	Agriculture of Data*
Personalised Medicine*	Clean steel – low-carbon steelmaking	Zero-emission road transport	Safe & Sustainable Food System*
Pandemic Preparedness* <i>Co-funded or co-programmed</i>	Processes4Planet	Built4People	
	Global competitive space systems**	Clean Energy Transition	
		Driving Urban Transitions	

- Institutionalised Partnerships (Art 185/7)
- Institutionalised Partnerships / EIT KICs
- Co-Programmed
- Co-Funded

\* Calls with opening dates in 2023-24  
 \*\* Calls with opening dates not before 2022

## PILLAR III - Innovative Europe

EIT (KNOWLEDGE & INNOVATION COMMUNITIES)	SUPPORT TO INNOVATION ECOSYSTEMS
InnoEnergy	Innovative SMEs
Climate	
Digital	
Food	
Health	
Raw Materials	
Manufacturing	
Urban Mobility	
Cultural and Creative Industries	

## CROSS-PILLARS II & III

European Open Science Cloud
-----------------------------



# Vision, mission and objectives

## Context:

- Majority of investments in Biomedical and Health research at EU level belong to MS
- Only 10% of these investments could be considered for joint and collaborative research and mostly comes from EU budget (Framework Programmes)

This Partnership brings the opportunity to increase European collaborative research funding by creating a **funding body** for joint programming in priority areas addressing European Public Health Needs



ERA4Health is defined as public funders of health research in ERA that jointly identify and implement a common funding strategy in priority areas to advance health research and develop innovation

# Specific objectives

- SO1. Support relevant medical research including in clinical fields and in intervention areas (prevention, diagnosis, treatment)
- SO2. Improve the utilisation of existing health technologies in clinical practice
- SO3. Build capacity, in particular in conducting IICs at European scale
- SO4. Implement and develop RRI in multiple ways (Partnership operationalization, calls, in project evaluation and monitoring)
- SO5. Promote open access and data sharing including by adhering to the FAIR (findability, accessibility, interoperability, and reusability) data principles
- SO6. Communicate and disseminate research outcomes, in particular to decision makers, the need of citizen's and patients for preventing, diagnoses and treat diseases

# Expected Outcomes (I)

- Based on a **trusted governance** and effective working modalities, research funders, health policy-makers and the research community work together in order to **identify and prioritise topics of common interest and European benefit**;
- Research funders and policy-makers:
  - support the generation of knowledge related, but not limited, to **cardiovascular diseases, diet related diseases and nano-medical technologies**, and have access to and make use of the evidence on the benefits and drawbacks of health interventions, in particular for optimising clinical management, personalised medicine and avoiding overtreatment;
  - have overcome the main obstacles to test health interventions at European level, therefore, the research community, independently from private interest, **conducts large-scale Investigator-Initiated Clinical Studies of various health interventions addressing important public health needs** in a seamless way, effectively addressing known challenges related to, for example, appropriate study design, ethics (including special patient groups), regulatory and institutional approvals, patient recruitment, management of informed consent, as well as, bio banking of human samples;

## Expected Outcomes (II)

- Public health research systems in the ERA are **more effective and integrated**. Utilization of health services, preventative measures, technologies, tools and digital solutions are more cost-effective;
- Research funders **double the coordinated** health research capacity from an estimated 10% (of public or private but public oriented funding) to 20% of the total investment;
- Health and care authorities, policymakers and other stakeholders use the research results to **develop evidence-based strategies and policies**, and deploy good practices to European countries and regions;
- Patients and citizens are more knowledgeable about disease threats and contribute to a **patient-centred decision-making process**, assuring better adherence to knowledge-based disease management strategies and policies (including for controlling outbreaks and emergencies);
- Countries cooperate better and use context-specific knowledge and evidence to make their **health and care systems more sustainable and resilient** with respect to upcoming needs and crises.

# Implementation Phases

## Phase 1

- Integrate selected European initiatives and implement joint calls focused on **nutrition- and lifestyle-related diseases, cardiovascular diseases and nanomedicine**
- Establishing a supporting framework to international IICs. Test the possibility to carry out joint calls on IICs
- Duration: 2 years

Health Programme  
Committee

## Phase 2

- Launching calls on priority areas
- Launching multinational calls for **investigator initiated clinical studies in priority areas**
- Duration: 5 years

EU Budget for Phase 1: 30 M€

EU Budget for Phase 2: 80 M€

Total Budget: 100 M€

Total Budget: 266 M€

# Activities

Management and Coordination (Pillar 0)

Pillar 1 Strategic  
planning

Pillar 2 Joint funding activities

Pillar 3 Transversal  
activities

Annual Work  
Plans, Priority  
settings and Topic  
selection

Annual calls for  
R&I activities

Investigator  
Initiated  
Clinical Studies

Capacity building,  
RRI, Monitoring  
and Evaluation,  
Sustainability



# Governance structure




# ERA4Health Partners

## **Grant Signatory**

The organization who signs the Grant Agreement with the European Commission, i.e. beneficiary of the Partnership, and is fully responsible towards the European Commission for implementing the Grant Agreement and for complying with all its obligations.

## **Affiliated Entity**


The beneficiary remains responsible towards the granting authority for the work carried out by the affiliated entity.



# Calendar and overall process of the Partnership Preparation



# Calendar and overall process of the Partnership Preparation





Thank you so much!

Ignacio Baanante  
[ibaanante@isciii.es](mailto:ibaanante@isciii.es)  
Institute of Health Carlos III, Spain

